Fenwick & West LLP represented Amyris, Inc. (NASDAQ: AMRS) in its initial public offering. Amyris, based in Emeryville, CA, is building an integrated renewable products company by applying their industrial synthetic biology technology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. They genetically modify microorganisms, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into potentially thousands of target molecules. The offering raised approximately $97.5 million for Amyris. Morgan Stanley & Co., Goldman, Sachs & Co. and J.P. Morgan Securities LLC acted as joint book-running managers for the offering. Itaú USA Securities Inc. and Stifel Nicolaus Weisel acted as co-managers for the offering.
The Fenwick & West transaction team included corporate attorneys Gordy Davidson, Sayre Stevick, Dan Winnike, Horace Nash, Michael Esquivel, Mariana Antcheva, Kristine Di Bacco, Andy Stewart and Marshall Mort; executive compensation and employee benefits attorneys Scott Spector and John Ludlum; and technology transactions attorneys Mark Ostrau.
Fenwick & West provides comprehensive legal services to technology, cleantech and life sciences clients of national and international prominence. The firm has been ranked by American Lawyer Media and Global Securities as one of the top 10 IPO counsel in the United States, by Bloomberg as one of the top 10 Global Equity IPO Manager Advisors and by Corporate Board Member as one of the top 5 corporate law firms in the San Francisco Bay Area for publicly traded companies.
Fenwick & West has a long and proud history of working with companies at the forefront of alternative energy and other cleantech-related technologies. Today, we represent a variety of companies in all areas of energy consumption, power management, and alternative fuels and materials.